Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Experimental and clinical evidence supports the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory medication that is indicated for the treatment of gout and pericarditis. METHODS: We performed a randomized, double-blind trial involving patients recruited within 30 days after a myocardial infarction. The patients were randomly assigned to receive either low-dose colchicine (0.5 mg once daily) or placebo. The primary efficacy end point was a composite of death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina leading to coronary revascularization. The components of the primary end point and safety were also assessed. RESULTS: A total of 4745 patients were enrolled; 2366 patients were assigned to the colchicine group, and 2379 to the placebo group. Patients were followed for a median of 22.6 months. The primary end point occurred in 5.5% of the patients in the colchicine group, as compared with 7.1% of those in the placebo group (hazard ratio, 0.77; 95% confidence interval [CI], 0.61 to 0.96; P = 0.02). The hazard ratios were 0.84 (95% CI, 0.46 to 1.52) for death from cardiovascular causes, 0.83 (95% CI, 0.25 to 2.73) for resuscitated cardiac arrest, 0.91 (95% CI, 0.68 to 1.21) for myocardial infarction, 0.26 (95% CI, 0.10 to 0.70) for stroke, and 0.50 (95% CI, 0.31 to 0.81) for urgent hospitalization for angina leading to coronary revascularization. Diarrhea was reported in 9.7% of the patients in the colchicine group and in 8.9% of those in the placebo group (P = 0.35). Pneumonia was reported as a serious adverse event in 0.9% of the patients in the colchicine group and in 0.4% of those in the placebo group (P = 0.03). CONCLUSIONS: Among patients with a recent myocardial infarction, colchicine at a dose of 0.5 mg daily led to a significantly lower risk of ischemic cardiovascular events than placebo. (Funded by the Government of Quebec and others; COLCOT ClinicalTrials.gov number, NCT02551094.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trials have shown that targeted inhibition of this inflammatory pathway, as measured by changes in CRP concentrations, can reduce the rate of cardiovascular events.5, 6, 7”
From Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials (2023) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This was also not an isolated finding as a similar reduction of CVD risk linked to reduction of inflammation was reported in the COLCOT trial when participants were given low‐dose colchicine (a standard anti‐inflammatory drug) (Tardif et al., 2019).”
From Treatment of periodontitis and C ‐reactive protein: A systematic review and meta‐analysis of randomized clinical trials (2023) · cites this paper as Tardif et al., 2019
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Reduction in LDL-C has been strongly associated with improved cardiovascular outcomes, and 3 recent trials have demonstrated favorable effects with anti-inflammatory therapies.[21][22][23][24]”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [23]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Reduction in LDL-C has been strongly associated with improved cardiovascular outcomes, and 3 recent trials have demonstrated favorable effects with anti-inflammatory therapies.[21][22][23][24]”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [23]
Experimental — accuracy not yet measuredIn the citing paper
“However, when appraised together, the evidence supports apolipoprotein B as being necessary for lipid-mediated atherogenesis by LDL-C to occur. 57,58 .”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [58]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
The Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain
Ravelli, R. B. G., Gigant, B., Curmi, P. A., Jourdain, I., Lachkar, S., Sobel, A., & Knossow, M. (2004) · Nature · doi:10.1038/nature02393 · Cited by 1,630
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Ridker, P. M., Everett, B. M., Pradhan, A., MacFadyen, J. G., Solomon, D. H., Zaharris, E., Mam, V., Hasan, A., Rosenberg, Y., Iturriaga, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1809798 · Cited by 1,317
Self-citationLow-Dose Colchicine for Secondary Prevention of Cardiovascular Disease
Nidorf, S. M., Eikelboom, J. W., Budgeon, C. A., & Thompson, P. L. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.027 · Cited by 1,054
Semiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Imazio, M., Bobbio, M., Cecchi, E., Demarie, D., Demichelis, B., Pomari, F., Moratti, M., Gaschino, G., Giammaria, M., Ghisio, A., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.542738 · Cited by 614
Cited by
Items 501–600 of 1,006
Vaccination in Atherosclerosis
Nettersheim, F. S., Vore, L. D., & Winkels, H. (2020) · Cells · doi:10.3390/cells9122560 · Cited by 50
“Nevertheless, a protective effect on cardiovascular diseases or overall mortality has yet to be demonstrated [11,12].”
BackgroundEl‐Malla, S. F., Elshenawy, E. A., Hammad, S. F., & Mansour, F. R. (2021) · Journal of Fluorescence · doi:10.1007/s10895-021-02698-0 · Cited by 45
Goeller, M., Achenbach, S. S., Duncker, H., Dey, D., & Marwan, M. (2021) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000583 · Cited by 49
CXCR4-Targeted Imaging of Post-Infarct Myocardial Tissue Inflammation
Werner, R. A., Koenig, T., Diekmann, J., Haghikia, A., Derlin, T., Thackeray, J. T., Napp, L. C., Wester, H., Roß, T. L., Schaefer, A., et al. (2021) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2021.08.013 · Cited by 49
Percutaneous Coronary Revascularization
Serruys, P. W. J. C., Ono, M., Garg, S., Hara, H., Kawashima, H., Pompilio, G., Andreini, D., Holmes, D. R., Onuma, Y., & King, S. B. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.05.024 · Cited by 50
Bikomeye, J. C., Beyer, A., Kwarteng, J. L., & Beyer, K. M. M. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19042426 · Cited by 45
Toner, Y. C., Ghotbi, A. A., Naidu, S., Sakurai, K., van Leent, M. M. T., Jordan, S., Ordikhani, F., Amadori, L., Sofias, A. M., Fisher, E. L., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-09590-2 · Cited by 50
Cimmino, G., Muscoli, S., Rosa, S. D., Cesaro, A., Perrone, M. A., Selvaggio, S., Selvaggio, G., Aimo, A., Pedrinelli, R., Mercuro, G., et al. (2023) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001450 · Cited by 48
Buono, M. G. D., Bonaventura, A., Vecchié, A., Moroni, F., Golino, M., Bressi, E., Ponti, R. D., Dentali, F., Montone, R. A., Kron, J., et al. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14110 · Cited by 53
Contributions of Inflammation to Cardiometabolic Heart Failure with Preserved Ejection Fraction
Thorp, E. B., & Filipp, M. E. (2024) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-111523-023405 · Cited by 51
Role of Colchicine in Stroke Prevention: An Updated Meta-Analysis
Masson, W. M., Lobo, M., Molinero, G., Masson, G., & Cobo, A. L. (2020) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2020.104756 · Cited by 46
What To Tell Your Patient With Clonal Hematopoiesis And Why: Insights From Two Specialized Clinics
Steensma, D. P., & Bolton, K. L. (2020) · Blood · doi:10.1182/blood.2019004291 · Cited by 14
Colchicine reduces lung injury in experimental acute respiratory distress syndrome
Dupuis, J., Sirois, M. G., Rhéaume, É., Nguyen, Q. T., Clavet‐Lanthier, M., Brand, G., Mihalache-Avram, T., Théberge-Julien, G., Charpentier, D., Rhainds, D., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242318 · Cited by 47
Self-citationMacrophage Polarization in the Perivascular Fat Was Associated With Coronary Atherosclerosis
Farias‐Itao, D. S., Pasqualucci, C. A., de Andrade, R. A., da Silva, L. F. F., Yahagi‐Estevam, M., Lage, S. G., Leite, R. E. P., Campo, A. B., & Suemoto, C. K. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023274 · Cited by 47
The Amino Acid Homoarginine Inhibits Atherogenesis by Modulating T-Cell Function
Nitz, K., Lacy, M., Bianchini, M., Wichapong, K., Avcilar-Kücükgöze, I., Bonfiglio, C. A., Migheli, R., Wu, Y., Burger, C., Li, Y., et al. (2022) · Circulation Research · doi:10.1161/circresaha.122.321094 · Cited by 47
Navar, A. M., Fine, L. J., Ambrosius, W. T., Brown, A., Douglas, P. S., Johnson, K., Khera, A. V., Lloyd-Jones, D., Michos, E. D., Mujahid, M., et al. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100430 · Cited by 43
“low-cost generic medication, demonstrated 23–31% reductions in rates of cardiovascular events among adults with established ASCVD [70,71].”
BackgroundInfluentialWang, J., Chen, Z., Dai, Q., Zhao, J., Wei, Z., Hu, J., Sun, X., Xie, J., & Xu, B. (2020) · Basic Research in Cardiology · doi:10.1007/s00395-020-0800-8 · Cited by 45
Liang, B., Li, M., Deng, Q., Wang, C., Rong, J., He, S., Xiang, Y., & Zheng, F. (2020) · Annals of Translational Medicine · doi:10.21037/atm-19-4728 · Cited by 44
“Lately, the COLCOT trials including 4,745 myocardial infarction participants reported that anti-inflammatory medication colchicine significantly reduced the risk of ischemic cardiovascular events (3).”
BackgroundApoB-Specific CD4+ T Cells in Mouse and Human Atherosclerosis
Marchini, T., Hansen, S., & Wolf, D. (2021) · Cells · doi:10.3390/cells10020446 · Cited by 53
“Likewise, anti‐inflammatory treatments target‐ ing the pro‐inflammatory cytokine IL‐1β [17] and by colchicine [18,19] prevent the pro‐ gression of cardiovascular disease.”
BackgroundVIu, M., Orlova, Y. A., Геннадьевна, П. А., Павликова, Е. П., Akopyan, Z. A., Мацкеплишвили, С. Т., Малахов, П. С., Krasnova, T. N., Seredenina, E. M., Potapenko, A. V., et al. (2021) · Kardiologiia · doi:10.18087/cardio.2021.2.n1560 · Cited by 43
Xu, J., Hao, X., Zhan, R., Jiang, X., Jin, A., Xue, J., Cheng, A., Liu, J., Lin, J., Meng, X., et al. (2022) · Stroke · doi:10.1161/strokeaha.121.034924 · Cited by 45
Calcific aortic stenosis: omics-based target discovery and therapy development
Blaser, M. C., Bäck, M., Lüscher, T. F., & Aikawa, E. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehae829 · Cited by 45
“After notable reductions of cardiovascular events in patients with chronic CAD, 133 interest grew in repurposing the anti-inflammatory alkaloid colchicine towards other cardiovascular indications.”
Effect of Biologics on Cardiovascular Inflammation: Mechanistic Insights and Risk Reduction
Fragoulis, G., Σουλαϊδόπουλος, Σ., Sfikakis, P. P., Dimitroulas, T., & Kitas, G. D. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s282691 · Cited by 47
“In COLCOT, treatment with colchicine over a 2-year period led to a 23% reduction in the recurrence of major cardiovascular events, including death from cardiovascular causes, myocardial infarction, stroke and unstable angina resulting in coronary interventions, compared to placebo.(40)”
BackgroundMethodCauses of Death in People With Cardiovascular Disease: A UK Biobank Cohort Study
Drozd, M., Pujades‐Rodríguez, M., Sun, F., Franks, K. N., Lillie, P. J., Witte, K. K., Kearney, M. T., & Cubbon, R. M. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.023188 · Cited by 44
Canonical and non-canonical functions of NLRP3
Accogli, T., Hibos, C., & Végran, F. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.01.001 · Cited by 51
Association of Autoimmune Diseases With Coronary Atherosclerosis Severity and Ischemic Events
Mortensen, M. B., Jensen, J. M., Sand, N. P. R., Kragholm, K. H., Blaha, M. J., Grove, E. L., Sørensen, H. T., Olesen, K. K. W., Mæng, M., Løgstrup, B. B., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.04.030 · Cited by 49
Targeting Inflammatory Pathways in Atherosclerosis: Exploring New Opportunities for Treatment
d’Aiello, A., Filomia, S., Brecciaroli, M., Sanna, T., Pedicino, D., & Liuzzo, G. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01241-3 · Cited by 52
“The reduction in clinical outcomes did not coincide with a significant parallel decrease in CRP levels compared to placebo, highlighting how colchicine acts through a different inflammatory pathway [50].”
BackgroundCacciatore, S., Andaloro, S., Bernardi, M., Manzanas, A. O., Spadafora, L., Figliozzi, S., Asher, E., Rana, J. S., Ecarnot, F., Gragnano, F., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073071 · Cited by 58
Targeting Inflammation After Myocardial Infarction
Mahtta, D., Sudhakar, D., Koneru, S., Silva, G. V., Alam, M., Virani, S. S., & Jneid, H. M. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01358-2 · Cited by 49
Bellinge, J. W., Francis, R. J., Lee, S. C., Phillips, M. R., Rajwani, A., Lewis, J. R., Watts, G. F., & Schultz, C. J. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315364 · Cited by 45
Luo, P., Wang, Y., Zhao, C., Guo, J., Shi, W., Ma, H., Liu, T., Yan, D., Huo, S., Wang, M., et al. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173822 · Cited by 45
Metabolic Consequences of Efferocytosis and Its Impact on Atherosclerosis
Yurdagul, A. (2021) · Immunometabolism · doi:10.20900/immunometab20210017 · Cited by 42
“The recent success of the CANTOS and COLCOT clinical trials indicate that lowering inflammation is a critical arm of the treatment strategy to decrease the burden of atherosclerosis [5,6].”
BackgroundLow-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review
Ferri, N., Ruscica, M., Fazio, S., & Corsini, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040943 · Cited by 51
“The recent FDA approval of colchicine for decreasing CV events could have a positive impact for a combination therapy aimed at controlling dyslipidemia and chronic inflammation [139,140].”
ApoB100 and Atherosclerosis: What’s New in the 21st Century?
Kounatidis, D. C., Vallianou, N. G., Poulaki, A., Evangelopoulos, A. A., Panagopoulos, F., Stratigou, T., Geladari, E. V., Karampela, Ι., & Dalamaga, Μ. (2024) · Metabolites · doi:10.3390/metabo14020123 · Cited by 56
“…NLRP3 inhibitor, has been reported to be beneficial in reducing cardiovascular events in individuals with coronary artery disease (CAD), as shown in the Colchicine Cardiovascular Outcomes Trial and the Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease Trial [164,165].”
BackgroundTrimarchi, G., Pizzino, F., Lilli, A., Caterina, A. R. D., Esposito, A., Dalmiani, S., Mazzone, A., Bella, G. D., Berti, S. L., & Paradossi, U. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206059 · Cited by 42
Bytyçi, I., Bajraktari, G., Penson, P. E., Henein, M. Y., Banach, M., & (ILEP), T. I. L. E. P. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15041 · Cited by 44
“6 months, the study found significant benefit of early administration of colchicine on a composite endpoint including CV death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina requiring coronary revascularization.(18) These results support what has previously been reported in Colchicine i…”
ResultTabbalat, R. A., Alhaddad, I. A., Hammoudeh, A. J., Khader, Y. S., Khalaf, H. A., Obaidat, M., & Barakat, J. (2020) · Journal of International Medical Research · doi:10.1177/0300060520939832 · Cited by 40
“Diarrhea occurred at equal rates in both groups.(21) The results of these trials confirmed that low-dose colchicine was beneficial against various cardiovascular diseases.”
ResultThe Role of Colchicine in Atherosclerosis: From Bench to Bedside
González, L., Bulnes, J. F., Paz, O. M., Venturelli, P. M., & Martínez-Rodríguez, G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071395 · Cited by 47
“5 mg BID) or placebo within 30 days post-MI [137].”
BackgroundHosseini, S. H., Talasaz, A. H., Alidoosti, M., Tajdini, M., Tassell, B. W. V., Etesamifard, N., Kakavand, H., Jalali, A., Aghakouchakzadeh, M., Gheymati, A., et al. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001317 · Cited by 42
Wang, Z., Xu, H., Chen, M., Lu, Y., Zheng, L., & Ma, L. (2022) · Cell Biology and Toxicology · doi:10.1007/s10565-022-09767-5 · Cited by 42
Ma, Z., Chen, J., Jin, K., & Chen, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.947959 · Cited by 40
“(8) Canada Multicenter, triple-blind RCTs ACS and CCS patients undergoing PCI 2,366 2,379 60.”
InfluentialAlexander, M. R., Dale, B. L., Smart, C. D., Elijovich, F., Wogsland, C. E., Lima, S. M., Irish, J. M., & Madhur, M. S. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2022.09.007 · Cited by 46
Inflammation as a therapeutic target in heart failure with preserved ejection fraction
Peh, Z. H., Dihoum, A., Hutton, D. L., Arthur, J. S. C., Rena, G., Khan, F., Lang, C. C., & Mordi, I. R. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1125687 · Cited by 50
“The concept of using colchicine for chronic cardiovascular disease was tested in the COLCOT (108) trial.”
BackgroundChong, S. Y., Wang, X., van Bloois, L., Huang, C., Sayed, N., Zhang, S., Ting, H. J., Nair, V., Lin, Y., Lou, C. K. L., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.06.035 · Cited by 52
Slysz, J., Sinha, A., DeBerge, M., Singh, S., Avgousti, H., Lee, I., Glinton, K. E., Nagasaka, R., Dalal, P., Alexandria, S. J., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.171359 · Cited by 44
“Pharmaco-interventions broadly targeting inflammation in atherosclerosis have yielded mixed results, depending on the biological and clinical target studied (3–5).”
Zhou, H., Khan, D., Hussain, S. M., Gerdes, N., Hagenbeck, C., Rana, M., Cornelius, J. F., & Muhammad, S. (2023) · Journal of Inflammation · doi:10.1186/s12950-023-00366-7 · Cited by 45
“In clinical trials, a daily dose of 0.5 mg of colchicine lowered the risks of cardiovascular events in patients [28, 29].”
BackgroundInfluentialFerreira, J. P., Vasques‐Nóvoa, F., Neves, J. S., Zannad, F. M., & Leite-Moreira, A. F. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117461 · Cited by 43
Bashir, B., Schofield, J., Downie, P., France, M., Ashcroft, D. M., Wright, A. K., Romeo, S., Gouni-Berthold, I., Maan, A., Durrington, P. N., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1389106 · Cited by 40
Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function
Zheng, T. J., Lofurno, E. R., Melrose, A. R., Lakshmanan, H. H. S., Pang, J., Phillips, K. G., Fallon, M. E., Kohs, T. C. L., Ngo, A. T. P., Shatzel, J. J., et al. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00296.2020 · Cited by 46
Hafiane, A., & Daskalopoulou, S. S. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106157 · Cited by 47
Immunity and inflammation in cardiovascular disorders
Boyalla, V., Gallego-Colón, E., & Spartalis, Μ. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03185-z · Cited by 41
“List of abbreviations CANTOS Canakinumab Anti-inflammatory Thrombosis Outcomes Study CIRT Cardiovascular Inflammation Reduction Trial COLCOT Colchicine Cardiovascular Outcomes Trial CVD Cardiovascular Disease CV Cardiovascular Acknowledgements The authors would like to thank those researchers who contribute to the BMC…”
BackgroundInfluentialSchooling, C., Zhao, J., Au Yeung, S., & Leung, G. (2020) · eLife · doi:10.7554/elife.58567 · Cited by 39
“, 2018), which may be reversed by anakinra possibly outweighing the benefits for IHD of suppressing inflammation (Tardif et al., 2019).”
BackgroundJin, F., Li, J., Guo, J., Doeppner, T. R., Hermann, D. M., Yao, G., & Dai, Y. (2021) · European Heart Journal Open · doi:10.1093/ehjopen/oeab022 · Cited by 41
Miceli, G., Basso, M. G., Rizzo, G., Pintus, C., & Tuttolomondo, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314914 · Cited by 47
Yang, L., Yue, Q., Fang, F., Zhang, Y., Liu, P., Zhang, Z., Wang, G., Chen, S., Wu, S., & Yang, X. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01826-3 · Cited by 47
“According to the grouping in previous studies related to residual risk [13, 16], we divided participants into four groups: those with no residual risk, LDL-C < 1.”
MethodGonzalez, A. L., Dungan, M. M., Smart, C. D., Madhur, M. S., & Doran, A. C. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0284 · Cited by 46
Bergamaschi, L., Pavon, A. G., Angeli, F., Tuttolomondo, D., Belmonte, M., Armillotta, M., Sansonetti, A., Foà, A., Paolisso, P., Baggiano, A., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13122083 · Cited by 44
“The role of coronary inflammation in the pathogenesis of atherosclerotic plaque instability is now well-established [92,93].”
BackgroundLiu, W., Hardaway, B. D., Kim, E., Pauli, J., Wettich, J. L., Yalçınkaya, M., Hsu, C.-C., Xiao, T., Reilly, M. P., Tabas, I. A., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci182939 · Cited by 42
Cholesterol crystals in the pathogenesis of atherosclerosis
Baumer, Y., Irei, J. S., & Boisvert, W. A. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01100-3 · Cited by 55
Katsanos, A. H., Palaiodimou, L., Price, C., Giannopoulos, S., Lemmens, R., Kosmidou, M. S., Georgakis, M. K., Weimar, C., Kelly, P. J., & Tsivgoulis, G. K. (2020) · European Journal of Neurology · doi:10.1111/ene.14198 · Cited by 41
“First, it should be highlighted that the effect estimate provided by the current meta-analysis is mostly driven by the most recent large scale trial [5].”
BackgroundResultInfluentialCardiovascular magnetic resonance imaging for inflammatory heart diseases
Lewis, A., Burrage, M. K., & Ferreira, V. M. (2020) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2019.12.09 · Cited by 45
“Immune cells and their roles within the cardiovascular system are now a major focus of interest and are promising therapeutic targets (5,6).”
BackgroundCirillo, P. L., Taglialatela, V., Pellegrino, G., Morello, A., Conte, S., Serafino, L. D., & Cimmino, G. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02121-8 · Cited by 39
Premature Atherosclerotic Cardiovascular Disease: What Have We Learned Recently?
Mahtta, D., Khalid, U., Misra, A., Samad, Z. Z., Nasir, K., & Virani, S. S. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00862-8 · Cited by 42
How Single-Cell Technologies Have Provided New Insights Into Atherosclerosis
Eberhardt, N., & Giannarelli, C. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.315849 · Cited by 41
Makris, A. P., Barkas, F., Sfikakis, P. P., Liberopoulos, E. N., Filippatos, T. D., Ray, K. K., & Agouridis, A. P. (2023) · Atherosclerosis Plus · doi:10.1016/j.athplu.2023.09.001 · Cited by 41
Effects of lifestyle factors on leukocytes in cardiovascular health and disease
Janssen, H., Koekkoek, L. L., & Świrski, F. K. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00931-w · Cited by 48
“The important role of chronic systemic inflammation in CVD has been proven experimentally 5 , and clinical trials in patients with atherosclerotic CVD have shown that interventions targeting inflammation, although associated with complications, potentially improve outcomes in selected patients 6–8 .”
Characteristics of patients with recurrent acute myocardial infarction after MINOCA
Ciliberti, G., Guerra, F., Pizzi, C., Merlo, M., Zilio, F., Bianco, F., Mancone, M., Zaffalon, D., Gioscia, R., Bergamaschi, L., et al. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.10.006 · Cited by 38
Fede, M. S., Daziani, G., Tavoletta, F., Montana, A., Compagnucci, P., Goteri, G., Neri, M., & Busardò, F. P. (2025) · Cells · doi:10.3390/cells14191509 · Cited by 54
Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes
Kaul, S., Gupta, M., Bandyopadhyay, D., Hajra, A., DEEDWANIA, P. C., Roddy, E., Mamas, M. A., Klein, A. L., Lavie, C. J., Fonarow, G. C., et al. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00459-1 · Cited by 39
Vascular and Cardiac Oxidative Stress and Inflammation as Targets for Cardioprotection
Daiber, A., Steven, S., Euler, G., & Schulz, R. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210125155821 · Cited by 46
Ponticelli, C. E., & Campise, M. (2021) · Kidney International · doi:10.1016/j.kint.2021.04.016 · Cited by 44
Resident Macrophages and Their Potential in Cardiac Tissue Engineering
Suku, M., Forrester, L. M., Biggs, M. J. P., & Monaghan, M. G. (2022) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2021.0036 · Cited by 44
“Although COLCOT had 4745 patients with recent MI (less than 30 days), LoDOCO2 had 5522 patients with chronic coronary artery disease and both the studies showed a reduction in the incidence of adverse cardiac events such as MI, stroke, cardiovascular death etc.(81,82) However, colchicine, being associated with an incr…”
BackgroundLuo, Y., Guo, Y., Wang, H. H., Yu, M., Hong, K. W., Li, D., Li, R., Wen, B., Hu, D., Chang, L., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103725 · Cited by 44
Noonan, J. E., Bobik, A., & Peter, K. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15356 · Cited by 38
“The COLCOT study, exploring colchicine treatment in patients after MI, also saw a significant reduction in cardiovascular events (Tardif et al., 2019).”
The Role of C-reactive Protein in Patient Risk Stratification and Treatment
Arroyo‐Espliguero, R., Viana-Llamas, M. C., Silva, J. A., & y, P. A. (2021) · European Cardiology Review · doi:10.15420/ecr.2020.49 · Cited by 46
Díaz, R., Orlandini, A., Castellana, N., Caccavo, A., Corral, P., Corral, G., Chacón, C., Lamelas, P. M., Botto, F. O., Díaz, M. L., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.41328 · Cited by 37
Self-citationBone marrow inflammatory memory in cardiometabolic disease and inflammatory comorbidities
Mitroulis, I., Hajishengallis, G., & Chavakis, T. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad003 · Cited by 47
“…Additionally, anti-inflammatory treatment of patients with previous myocardial infarction or patients with chronic coronary disease with colchicine 14,15 or treatment of patients after myocardial infarction that had a C-reactive protein concentration > 2 mg/L with canakinumab, 16 an antibody…”
BackgroundAdvances in Clinical Imaging of Vascular Inflammation
West, H. W., Dangas, K., & Antoniades, C. A. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.10.007 · Cited by 54
Pan, W., Zhou, G., Hu, M., Li, G., Zhang, M., Yang, H., Li, K., Li, J., Liu, T., Wang, Y., et al. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-03729-x · Cited by 41
“Notably, all clinical trials that obtained significant cardiovascular benefits (CANTOS, COLCOT, and LoDoCo2) so far in terms of anti-inflammatory treat-ment for coronary heart disease target the NLRP3/IL1β inflammatory axis [11–13].”
BackgroundPan-vascular disease: what we have done in the past and what we can do in the future?
Wong, M., Dai, Y., & Ge, J. (2024) · Cardiology Plus · doi:10.1097/cp9.0000000000000078 · Cited by 40
Anti-ageing interventions for the treatment of cardiovascular disease
Abdellatif, M., Schmid, S., Fuerlinger, A., & Kroemer, G. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae177 · Cited by 52
“131,132 Similarly, the beneficial effects of SGLT2 inhibitors in HFpEF 133 have been linked to their anti-inflammatory properties.”
Cogan, E., Foulon, P., Cappeliez, O., Dollé, N., Vanfraechem, G., & Backer, D. D. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00428 · Cited by 38
“It is a class IIa recommendation in pericarditis (36), and can even be used after acute myocardial infarction (37).”
BackgroundHofeld, B. C., Puppala, V. K., Tyagi, S., Ahn, K. W., Anger, A., Jia, S., Salzman, N. H., Hessner, M. J., & Widlansky, M. E. (2021) · Scientific Reports · doi:10.1038/s41598-021-83252-7 · Cited by 42
Frenis, K., Helmstädter, J., Ruan, Y., Schramm, E., Kalinovic, S., Kröller‐Schön, S., Jiménez, M. T. B., Hahad, O., Oelze, M. W., Jiang, S., et al. (2021) · Basic Research in Cardiology · doi:10.1007/s00395-021-00869-5 · Cited by 42
“These results were supported by data the COLCOT study indicating that anti-inflammatory colchicine treatment decreased the risk of ischemic cardiovascular events in patients with a recent myocardial infarction [64].”
ResultPasqualetto, M. C., Tuttolomondo, D., Cutruzzolà, A., Niccoli, G., Dey, D., Greco, A., Martini, C., Irace, C., Rigo, F., & Gaibazzi, N. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.05.040 · Cited by 39
Kawabe, A., Yasu, T., Morimoto, T., Tokushige, A., Momomura, S., Sakakura, K., Node, K., Inoue, T., Ueda, S., & The CHD Collaborative Investigators (2021) · ESC Heart Failure · doi:10.1002/ehf2.13513 · Cited by 37
“During follow-up, 232 patients had a new AMI episode, which included 182 patients with non-fatal AMI.”
BackgroundMethodInfluentialMengozzi, A., Pugliese, N. R., Chiriacò, M., Masi, S., Virdis, A., & Taddei, S. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001109 · Cited by 45
Liu, H., Guo, Y., Zhu, C., Wu, N., Gao, Y., Xu, R., Dong, Q., Qian, J., Dou, K., & Li, J. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03448-x · Cited by 42
“Furthermore, recent trials of anti-inflammatory therapies targeted at specific inflammatory pathways have further demonstrated the efficacy for the prevention of cardiovascular events [26, 27].”
BackgroundAnti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine
Andreotti, F., Maggioni, A. P., Campeggi, A., Iervolino, A., Scambia, G., & Massetti, M. (2021) · European Heart Journal Supplements · doi:10.1093/eurheartj/suab084 · Cited by 39
Self-citationCommon NLRP3 inflammasome inhibitors and Covid-19: Divide and conquer
Batiha, G. E., Al-Gareeb, A. I., Rotimi, D., Adeyemı, O. S., & Al-Kuraishy, H. M. (2022) · Scientific African · doi:10.1016/j.sciaf.2022.e01407 · Cited by 39
“Colchicine is widely used in the management of acute gout, familial meditation fever, pericarditis, and other inflammatory disorders [64] .”
Heusch, G. (2023) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484231179613 · Cited by 36
Tan, H., Li, W., Pang, Z., Weng, X., Gao, J., Chen, J., Wang, Q., Li, Q., Yang, H., Dong, Z., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202303267 · Cited by 40
Yalçınkaya, M., Liu, W., Xiao, T., Abramowicz, S., Wang, R., Wang, N., Westerterp, M., & Tall, A. R. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100534 · Cited by 42
“The currently available anti-inflammatory therapies that broadly suppress the inflammasome reduced CVD in randomized clinical trials but also resulted in an increase in infectious complications, limiting their clinical adoption (13 – 15 , 50”
Role of Uremic Toxins in Vascular Inflammation Associated with Chronic Kidney Disease
Chermiti, R., Burtey, S., & Dou, L. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237149 · Cited by 44
Wijeratne, T., Menon, R., Sales, C., Karimi, L., & Crewther, S. G. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-4388 · Cited by 36
“The COLCOT trial involving 4,745 individuals, concluded that low-dose colchicine significantly reduced ischaemic cardiovascular events (77,78).”
BackgroundInfluentialSinh, P., & Cross, R. K. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaa258 · Cited by 37
Dey, A. K., Teague, H., Adamstein, N. H., Rodante, J. A., Playford, M. P., Chen, M. Y., Bluemke, D. A., Gelfand, J. M., Ridker, P. M., & Mehta, N. N. (2020) · Journal of cardiovascular computed tomography · doi:10.1016/j.jcct.2020.12.006 · Cited by 37
The multifaceted therapeutic value of targeting ATP-citrate lyase in atherosclerosis
Verberk, S. G. S., Kuiper, K. L., Lauterbach, M., Latz, E., & den Bossche, J. V. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.09.004 · Cited by 41
Exosomes in atherosclerosis: Convergence on macrophages
Yang, K., Xiao, Q., Niu, M., Pan, X., & Zhu, X. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.71862 · Cited by 39
“However, the CANTOS trial (blocking IL-1β with canakinumab) and the COLCOT trial (colchicine treatment) showed a reduced risk of cardiovascular events [88, 89].”
BackgroundSun, M., Dubé, M., Hennessy, T., Schultz, C. J., Barhdadi, A., Rhainds, D., Hillis, G. S., & Tardif, J. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.06.028 · Cited by 36
Self-citation
Metadata
- Authors
- Tardif, J.-C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., Berry, C., López-Sendón, J., Ostadal, P., Koenig, W., Angoulvant, D., Grégoire, J. C., Lavoie, M.-A., Dubé, M.-P., Rhainds, D., Provencher, M., Blondeau, L., Orfanos, A., L’Allier, P. L., Guertin, M.-C., & Roubille, F.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- From the Montreal Heart Institute (J.-C.T., R.I., J.C.G., M.-A.L., M.-P.D., D.R., P.L.L.) and the Montreal Health Innovations Coordinating Center (M.P., L.B., A.O., M.-C.G.), Montreal, Centre Hospitalier Régional de Lanaudière, Joliette (S.K.), and Institut de Cardiologie et Pneumologie de Québec, Quebec City (O.F.B.) — all in Canada; San Francisco General Hospital, San Francisco (D.D.W.); Estudios Clínicos Latinoamérica, Rosario, Argentina (R.D.); Associazione Nazionale Medici Cardiologi...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-12-26
- Volume
- 381
- Issue
- 26
- Pages
- 2497-2505
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2986700515
- Cited by
- 3,159
- References
- 20
- Citations by year
- 2026: 505 · 2025: 519 · 2024: 445 · 2023: 415 · 2022: 414 · 2021: 485 · 2020: 361 · 2019: 10
- FWCI
- 230.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- HAL (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion)
- Funders
- Government of Quebec
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- colchicine, myocardial infarction, anti-inflammatory therapy, inflammation in atherosclerosis, cardiovascular mortality, major adverse cardiovascular events, stroke, angina pectoris, diarrhea, pneumonia, drug safety, low-dose colchicine, secondary prevention, coronary revascularization, cardiac arrest, myocardial infarction recurrence, cardiovascular risk reduction, cost-effectiveness, quality of life
- MeSH terms
- Aged, Angina Pectoris, Anti-Inflammatory Agents, C-Reactive Protein, Cardiovascular Diseases, Colchicine, Double-Blind Method, Female, Humans, Male, Middle Aged, Myocardial Infarction, Recurrence, Biomarkers, Incidence, Proportional Hazards Models, Stroke, Kaplan-Meier Estimate, Intention to Treat Analysis, Percutaneous Coronary Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

